Comparison of Efficacy of Insulin Lispro 75/25 and Human Insulin Humulin 70/30 on Type 2 Diabetes Mellitus_West China Medical Journal

Authors：

DU Xiaomei

Department of Endocrinology and Metabolism, Dazhou Central Hospital, Dazhou, Sichuan 635000, P.R.China;

Corresponding?author：

Keywords：

2型糖尿病; 賴脯胰島素75/25; 優泌林70/30

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　對比分析胰島素類似物賴脯胰島素75/25和人胰島素優泌林70/30治療2型糖尿病對血糖的控制作用和安全性。　方法　選取2007年6月-2008年7月107例2型糖尿病患者，隨機分為兩組:賴脯胰島素75/25組54例，每日早、晚餐前10 min皮下注射賴脯胰島素75/25，劑量0.5～0.7 U/（kg?d）；優泌林70/30組53例，每日早、晚餐前30 min注射優泌林70/30，劑量0.7～1.0 U /（kg?d），治療2周后觀察患者日胰島素總量、血糖控制情況、體質量及低血糖發生率。　結果　治療2周后，賴脯胰島素75/25組FBG由（15.4±3.1） mmol/L降為（6.5±1.4） mmol/L（P lt;0.05）、PBG-2h由（22.2±6.5） mmol/L降至（9.23±2.51） mmol/L（P lt;0.05）；優泌林70/30組FBG由（14.9±3.0） mmol/L降為（6.7±1.7） mmol/L（P lt;0.05），PBG-2h由（21.7±7.3） mmol/L降至（11.10±2.73） mmol/L（P lt;0.05）。治療3個月后賴脯胰島素75/25組HbA1c水平明顯下降，與優泌林70/30組比較差異有統計學意義（P lt;0.05）；日胰島素用量賴脯胰島素75/25組較優泌林70/30組低（P lt;0.05），體質量變化及低血糖發生率兩組比較無統計差異性（P gt;0.05）。　結論　賴脯胰島素75/25治療2型糖尿病，HbA1c水平更低，達標患者的比例更高，具有良好的安全性及依從性。
【Abstract】　Objective　 To compare the clinical safety and effect of insulin analogues insulin lispro 75/25 and human insulin humulin 70/30 on type 2 diabetes mellitus.　Methods　 A total of 107 patients with type 2 diabetes mellitus from June 2007 to July 2008 were randomly divided into two groups: 54 patients in group A were injected with insulin lispro 75/25 [0.5-0.7 U/(kg?d)], twice per day, 10 minutes before each breakfast and dinner, and another 53 patients in group B were injected with human insulin humulin 70/30 [0.7-1.0 U/(kg?d)], twice per day, 30 minutes before each breakfast and dinner. The daily insulin dosage, level of blood glucose, body mass and the incidence of low blood sugar in the two groups were observed.　Results　 Two weeks after the treatment, the level of FBG decreased from (15.4±3.1) mmol/L to (6.5±1.4) mmol/L (P lt;0.05), and the level of PBG-2h decreased from (22.2±6.5) mmol/L to (9.23±2.51) mmol/L (P lt;0.05) in group A; the level of FBG decreased from (14.9±3.0) mmol/L to (6.7±1.7) mmol/L (P lt;0.05), and the level of PBG-2h decreased from (21.7±7.3) mmol/L to (11.10±2.73) mmol/L (P lt;0.05) in group B. Three months after the treatment, the level of HbA1c in group A decreased apparently, which differed much from that in group B (P lt;0.05). The daily dosage of insulin in group A was lower than that in group B (P lt;0.05); the differences in changes of body mass and the incidence of hypoglycemia between the two groups were not significant (P gt;0.05).　Conclusion　 The treatment with insulin lispro 75/25 for type 2 diabetes mellitus shows a good effect on HbA1c level control with safety and compliance.

Citation： DU Xiaomei. Comparison of Efficacy of Insulin Lispro 75/25 and Human Insulin Humulin 70/30 on Type 2 Diabetes Mellitus. West China Medical Journal, 2010, 25(11): 2012-2014. doi: Copy

1.	Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture[J]. Diabetes Care, 1997, 20(6): 1612-1614.
2.	Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group[J]. Diabetes, 1997, 46(4): 265-270.
3.	錢榮立. 糖尿病臨床指南[M]. 北京: 北京醫科大學出版社, 2000: 7-12.
4.	UK Prospective Diabetes Study Group. Quality of life in type 2 diabetes patients is effected by complications but not by intensive policies to improve blood glucuse or pressure control(UKPDS)[J]. Diabetes Care, 1999, 22(5): 1125.
5.	Malone JK, Wolthers T, Sun B, et al. Improvement in HbAlc in patients with type 2 diabetes with Humalog Mix 25 versus basal human insulin: a double-blind study[J]. J Appl Ther Res, 2004, 4(5): 19-25.
6.	葉任高, 陸再英. 內科學[M]. 6版. 北京: 人民衛生出版社, 2006: 815-820.
7.	Reviriego J, Herz M, Roach P, et al. Improved glycadmic control without increased risk of hypoglycaemia with a 25% insulin/lispro75% NPL mixture twice daily compared with NPH twice daily in patients with type2 diabetes[J]. J Appl Ther Res, 2004, 4(6): 3-9.
8.	Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study[J]. BMJ, 2000, 321(8): 405-412.
9.	Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it[J]. Diabetes Res Clin Pract, 1999, 43(2): 137-142.
10.	王金抒. 老年糖尿病131例臨床分析[J]. 華西醫學, 1995, 10(4): 121-123.
11.	Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, inslin lispro mix25 and insulin lispro mixso[J]. Clin Ther, 1999, 21(9): 523-534.

1. 　Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture[J]. Diabetes Care, 1997, 20(6): 1612-1614.
2. 　Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group[J]. Diabetes, 1997, 46(4): 265-270.
3. 　錢榮立. 糖尿病臨床指南[M]. 北京: 北京醫科大學出版社, 2000: 7-12.
4. 　UK Prospective Diabetes Study Group. Quality of life in type 2 diabetes patients is effected by complications but not by intensive policies to improve blood glucuse or pressure control(UKPDS)[J]. Diabetes Care, 1999, 22(5): 1125.
5. 　Malone JK, Wolthers T, Sun B, et al. Improvement in HbAlc in patients with type 2 diabetes with Humalog Mix 25 versus basal human insulin: a double-blind study[J]. J Appl Ther Res, 2004, 4(5): 19-25.
6. 　葉任高, 陸再英. 內科學[M]. 6版. 北京: 人民衛生出版社, 2006: 815-820.
7. 　Reviriego J, Herz M, Roach P, et al. Improved glycadmic control without increased risk of hypoglycaemia with a 25% insulin/lispro75% NPL mixture twice daily compared with NPH twice daily in patients with type2 diabetes[J]. J Appl Ther Res, 2004, 4(6): 3-9.
8. 　Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study[J]. BMJ, 2000, 321(8): 405-412.
9. 　Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it[J]. Diabetes Res Clin Pract, 1999, 43(2): 137-142.
10. 　王金抒. 老年糖尿病131例臨床分析[J]. 華西醫學, 1995, 10(4): 121-123.
11. 　Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, inslin lispro mix25 and insulin lispro mixso[J]. Clin Ther, 1999, 21(9): 523-534.

West China Medical Journal

Comparison of Efficacy of Insulin Lispro 75/25 and Human Insulin Humulin 70/30 on Type 2 Diabetes Mellitus

Abstract Full text Figures/Tables Video References Cited by

Format

Content